Phenytoin versus other antiepileptic drugs as treatments for status epilepticus in adults: a systematic review and meta-analysis

Eisei Hoshiyama,1,2 Junji Kumasawa,3 Masatoshi Uchida,1 Toru Hifumi,4 Takashi Moriya,5 Yasuhiko Ajimi,6 Yasufumi Miyake,6 Yutaka Kondo,7 Shoji Yokobori,8 and for the Japan Resuscitation Council (JRC) Neuroresuscitation Task Force and the Guidelines Editorial Committee*

1Department of Emergency and Critical Care Medical Center, Dokkyo Medical University, Tochigi, Japan, 2Department of Neurology, Dokkyo Medical University, Tochigi, Japan, 3Department of Critical Care Medicine, Sakai City Medical Center, Sakai, Japan, 4Department of Emergency and Critical Care Medicine, Emergency Medical Center, St. Luke’s International Hospital, Chuo, Japan, 5Department of Emergency and Critical Care Medicine Saitama Medical Center, Jichi Medical University, Tochigi, Japan, 6Department of Emergency Medicine, Teikyo University School of Medicine, Tokyo, Japan, 7Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Urayasu, Japan, and 8Department of Emergency and Critical Care Medicine, Nippon Medical School, Tokyo, Japan

Aim: Status epilepticus (SE) is a life-threatening neurological emergency. There is insufficient evidence regarding which antiepileptic therapy is most effective in patients with benzodiazepine-refractory convulsive SE. Therefore, this study aimed to evaluate intravenous phenytoin (PHT) and other intravenous antiepileptic medications for SE.

Methods: We searched PubMed, the Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi for published randomized controlled trials (RCTs) in humans up to August 2019. We compared outcomes between intravenous PHT and other intravenous medications. The important primary composite outcomes were the successful clinical cessation of seizures, mortality, and neurological outcomes at discharge. The reliability of the level of evidence for each outcome was compared using the Grading of Recommendations Assessment, Development, and Evaluation approach.

Results: A total of 1,103 studies were identified from the databases, and 10 RCTs were included in the analysis. The ratio of successful clinical seizure cessation was significantly lower (risk ratio [RR] 0.89; 95% confidence interval [CI], 0.82–0.97) for patients treated with intravenous PHT than with other medications. When we compared mortality and neurological outcomes at discharge, we observed no significant differences between patients treated with PHT and those treated with other medications. The RRs were 1.07 (95% CI, 0.55–2.08) and 0.91 (95% CI, 0.72–1.15) for mortality and neurological outcomes at discharge, respectively.

Conclusions: Our findings showed that intravenous PHT was significantly inferior to other medications in terms of the cessation of seizures. No significant differences were observed in mortality or neurological outcomes between PHT and other medications.

Key words: Neurological outcome, phenytoin, seizure cessation, status epilepticus

INTRODUCTION

Status epilepticus (SE) is a major medical emergency associated with significant neurological outcomes and mortality. The current definition of SE is 5 min or more of continuous clinical and/or electrographic seizure activity or recurrent seizure activity without recovery between seizures.1-3 Convulsive SE is defined as an acute epileptic condition characterized by continuous generalized convulsive seizures for at
least 5 min or two seizures without full recovery of consciousness between seizures. The adverse effects of SE include both indirect systemic problems arising from the convulsive state and direct neuronal injury. Most evidence supports the use of benzodiazepines as the initial treatment for SE. The American Epilepsy Society published a set of guidelines in which they recommended the intravenous (i.v.) administration of phenytoin (PHT), valproate (VPA), levetiracetam (LEV), or phenobarbital (PB) as the treatment for refractory convulsive SE. However, evidence regarding which drug is most effective in patients with benzodiazepine-refractory convulsive SE is insufficient.

Additionally, in a survey of critical care neurologists published in 2003, 95% of responders (n = 106) used fosphenytoin or PHT for the treatment of established SE. Thus, PHT is the oldest and most used drug for this purpose; but with the recent launch of new drugs, its effectiveness should be reexamined.

**Research question**

Which antiepileptic drugs (AEDs)—phenytoin or other medications—should be used in adult patients with benzodiazepine-refractory convulsive SE?

We identified randomized controlled trials (RCTs) for inclusion based on the research question and according to the PICO (participants, interventions, comparisons, and outcomes) criteria: participants, adults (≥15 years old) with SE; interventions, administration of drugs to treat SE in prehospital, emergency room settings; comparisons, administration of other antiepileptic medications; and outcomes, the primary outcomes were seizure cessation, mortality, and good neurological outcomes.

**METHODS**

In 2020, the Japan Resuscitation Council (JRC) Neuroresuscitation Task Force and the Guidelines Editorial Committee were established. The JRC Neuroresuscitation Task Force established six clinically relevant questions, and this systematic review was carried out based on these questions.

Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, we undertook a systematic review and meta-analysis. This study was registered in the University Hospital Medical Information Network (UMIN) of the National University Hospital Association, Japan (https://www.umin.ac.jp registration no. R000045525UMIN00039934). As this study was a systematic review with a meta-analysis, ethics committee approval was not required.

**Search strategies**

Databases such as MEDLINE (through PubMed), the Cochrane Central Register of Controlled Trials (CENTRAL), and Igaku Chuo Zasshi (ICHUSHI) were searched to retrieve relevant articles for the review. We searched for full-text RCTs carried out in humans published until August 2019. We used a combination of key terms and established a full search strategy (File S1).

**Study selection and inclusion criteria**

The study population of interest consisted of patients in settings ranging from prehospitalization to the emergency room who were suspected to have benzodiazepine-refractory convulsive SE. We did not restrict our analysis by country and included all severities and types of SE. Conference abstracts and animal studies were excluded. We only included studies that were written in English or Japanese.

We compared the outcomes between PHT and other medications. The critical outcomes in the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system were the successful clinical termination of seizures, mortality at discharge, and neurological outcome at discharge, as assessed by the functional independence measure (FIM; a good outcome was a FIM score ranging from 5 to 7, and a poor outcome was a score ranging from 1 to 4) or the modified Rankin Score (mRS; a good outcome was an mRS score ranging from 0 to 3, and a poor outcome was a score ranging from 4 to 6).

**Data extraction and management**

Two independent reviewers (EH and MU) screened the titles and summaries of the study and then reviewed the relevant full-text articles. Disagreements were reviewed until an agreement was reached. The two reviewers individually reviewed the full text of the articles included in the final selection. Disagreements were resolved by a third reviewer (JK). The flow diagram of our study, which was adapted from the PRISMA statement (2009), is shown in Fig. 1.

**Meta-analysis**

We undertook a meta-analysis because sufficient data were available according to the “Cochrane Handbook for Systematic Reviews of Interventions” and PRISMA guidelines. The results were summarized using a random effects model to facilitate the pooling of treatment effect estimates. Risk
ratios (RRs) and 95% confidence intervals (CIs) were calculated for dichotomous outcomes.

Heterogeneity between trials for each outcome was evaluated using the $I^2$ statistic. Heterogeneity was determined by calculating $I^2$ values, which were interpreted as follows: 0–40%, might not be important; 30–60%, may represent moderate heterogeneity; 50–90%, may represent substantial heterogeneity; and 75–100%, considerable heterogeneity. Quantification of heterogeneity is only one component of a wider investigation of variability across studies, the most important being diversity in clinical and methodological aspects. Meta-analysts must also consider the clinical implications of the observed degree of inconsistency across studies. A funnel plot was generated to investigate the potential for publication bias. Estimates were pooled using a random effects model. The meta-analysis was undertaken based on all published data and data made available by the authors of the original studies.

**Subgroup analysis**

We compared the outcomes between PHT and other medications. However, because other drugs contain many types of drugs, we compared PHT directly with each drug in regard to seizure cessation. Of the 10 RCTs, only four studies investigated mortality, and only two studies investigated neurological outcomes. Therefore, we did not undertake subgroup analyses of these parameters.

**Risk of bias assessment**

The Cochrane and GRADE system risk of bias tools were adopted to assess the quality of the included studies. Each study was assessed for: (i) random sequence generation (selection bias), (ii) allocation concealment (selection bias), (iii) the blinding of participants and personnel (performance bias), (iv) the blinding of related outcome
assessments (detection bias), (v) incomplete outcome data (attrition bias), (vi) selective reporting (reporting bias), (vii) other sources of bias. Studies were categorized as having a low, unclear, or high risk of bias in each domain. The risk of bias for each element was considered “high” when bias was present and likely to affect the outcomes and “low” when bias was absent or present but unlikely to affect the outcomes.\(^{15}\)

Two independent reviewers (EH and MU), chosen from among the authors, carried out the risk of bias assessments. Disagreements were resolved through discussion.

**Rating the certainty of evidence using the GRADE approach**

We used the GRADE tool to rate the quality of the evidence for the effect of i.v. PHT and other medications on adult patients with SE.\(^{16-19}\) The certainty of the evidence was assessed as high, moderate, low, or very low based on the evaluation of the risk of bias, inconsistency, indirectness, imprecision, and publication bias. We generated an evidence profile table using GRADEpro GDT (GRADEpro Guideline Development Tool software developed by Evidence Prime, available from https://gradepro.org). We received guidance regarding the use of the GRADE system from the Medical Information Network Distribution Service (MINDS), a Japanese educational center for the GRADE system. Two reviewers also discussed the results of the risk of bias assessment and achieved a consensus on the final determination.

We used Review Manager software (Cochrane systematic review software, version 5.3.5; The Nordic Cochrane Centre) to undertake the statistical analysis.

### RESULTS

**Search of published works**

We identified 1,103 studies from the electronic databases, and 1,090 studies were excluded because they were not RCTs. Finally, the full texts of 13 studies were reviewed, and 10 studies\(^{20-29}\) were included in the final analysis (Fig. 1).

**Study characteristics**

The 10 RCTs\(^{20-29}\) included 1,012 patients: 485 were assigned to the PHT group and 527 were assigned to the VPA, LEV, or PB group. The definition of SE was different in each RCT. No RCTs carried out in Japan compared the effect of i.v. PHT and other i.v. antiepileptic medications on the treatment of adults with SE as a second-line treatment. The individual characteristics of the trials included in this meta-analysis are shown in Table 1. The risk of bias was evaluated for each study, and the results are shown in the risk of bias summary in Fig. 2A–C (green [+], low risk; red [−], high risk).

**Outcomes**

The pooled RR for the cessation of seizures (10 RCTs, \(n = 1,012\))\(^{(20-29)}\) was statistically significant (RR 0.89; 95% CI, 0.82–0.97) (Fig. 3A), showing the superior effect of other medications compared to PHT. However, due to the overlap of other drugs, we compared PHT directly with each drug for effects on seizure cessation.

Therefore, we undertook the following subgroup analyses of seizure cessation. When performing pairwise comparisons of PHT and VPA, LEV, or PB, no significant differences were observed between PHT and the other medications. The pooled RRs were 0.91 (95% CI, 0.82–1.01), 1.00 (95% CI, 0.84–1.19), and 0.94 (95% CI, 0.75–1.18) for the comparison of seizure cessation induced by PHT and VPA (Fig. 4A), PHT and LEV (Fig. 4B), and PHT and PB (Fig. 4C), respectively.

Two hundred ninety-eight patients (four RCTs, \(n = 298\)) died: 149 had received PHT, and 149 had received other drugs (Fig. 3B). No significant differences were observed in mortality between PHT and the other medications (RR 1.07; 95% CI, 0.55–2.08).

No statistically significant relationship was found between drug choice and good neurological outcomes (two RCTs, \(n = 96\)) (RR 0.91; 95% CI, 0.72 to 1.15) (Fig. 3C).

**Certainty of evidence**

We have summarized the certainty of evidence in the evidence profile table (Table 2).

The certainty of evidence was rated as very low due to the serious risk of bias and indirectness and very serious imprecision with regard to mortality. The certainty of evidence for a good neurological outcome was very low because of the serious risk of bias, indirectness, and imprecision. The certainty of evidence for seizure cessation was low due to the serious risk of bias and indirectness. The overall certainty of the evidence was very low. No statistically significant heterogeneity in mortality or a good neurological outcome was observed between i.v. PHT and other i.v. medications (\(I^2 = 0\%\), \(\chi^2 = 0.19\), \(p = 0.98\); \(I^2 = 0\%\), \(\chi^2 = 0.86\), \(p = 0.35\), respectively). Statistically significant heterogeneity was not observed for seizure cessation between PHT and VPA or LEV.
| First author, year (country) | Definition of SE and inclusion criteria | Underlying etiology | No. of patients | Duration of SE | Interventions | Outcomes | Notes |
|-----------------------------|----------------------------------------|--------------------|----------------|---------------|---------------|---------|-------|
| Agarwal, 2007 (India)       | Continuous or repeated seizure activity >5 min without recovery of consciousness | Reported           | VPA 50 PHT 50  | VPA <2 h 60%, >2 h 40% PHT <2 h 52%, >2 h 48% | VPA 20 mg/kg i.v. PHT 20 mg/kg i.v. in hospital | Mortality Seizure control Adverse effects | DZP was given in doses of 0.2 mg/kg at 2 mg/min up to a maximum of 20 mg |
| Amiri-Nikpour, 2018 (Iran)  | Continuous generalized convulsive seizure lasting >5 min or two or more discrete seizures during which the patient did not return to baseline consciousness | Reported           | VPA 55 PHT 55  | NR            | VPA 30 mg/kg i.v. PHT 20 mg/kg i.v. in hospital | Mortality Seizure control Adverse effects | DZP was given in doses of 0.2 mg/kg at 2 mg/min up to a maximum of 20 mg |
| Chakravarthi, 2015 (India) | Continuous generalized convulsive seizure lasting >5 min or two or more discrete seizures during which the patient did not return to baseline consciousness | Reported           | PHT 22 LEV 22  | PHT 72.05 ± 48.57 (min) LEV 55.91 ± 73.75 (min) | PHT 20 mg/kg i.v. LEV 20 mg/kg i.v. in hospital | Mortality Seizure control Adverse effects Neurological outcome | LZP was given in doses of 0.1 mg/kg at 1 mg/min |
| Chitsaz, 2013 (Iran)        | Continuous generalized convulsive seizure lasting for approximately 5–20 min or no intervals of consciousness evident between the seizures | NR                 | VPA 15 PHT 15  | NR            | VPA 20 mg/kg i.v. PHT 20 mg/kg i.v. in hospital | Seizure control | DZP was given in doses of 0.15 mg/kg at 5 mg/min |
| First author, year (country) | Definition of SE and inclusion criteria | Underlying etiology | No. of patients | Duration of SE | Interventions | Outcomes | Notes |
|----------------------------|----------------------------------------|--------------------|----------------|----------------|---------------|---------|-------|
| Gilad, 2008 (Israel)       | Continued seizure activity for >30 min or two or more sequential seizures without full recovery between seizures | Reported           | VPA 18 PHT 9  | NR             | VPA 30 mg/kg i.v. | Seizure control | Adverse effects | LZP (0.1 mg/kg) |
| Gujjar, 2017 (Oman)        | Prolonged (>5 min) or recurrent generalized tonic–clonic seizure(s) with no return of consciousness between attacks or partial seizures persisting for more than 10 min | Reported           | LEV 22 PHT 30 | NR             | LEV 30 mg/kg i.v. | Mortality | Seizure control | LNZ 4 mg or DZP 5–10 mg over 2 min |
| Misra, 2006 (India)        | Two or more convulsive seizures without full recovery of consciousness between the seizures or continuous convulsive seizures lasting >10 min | Reported           | VPA 35 PHT 33 | VPA 1.76 ± 0.49 h PHT 1.70 ± 0.47 h | VPA 30 mg/kg i.v. PHT 18 mg/kg i.v. in hospital | Seizure control | Adverse effects |
| Mundlamuri, 2015 (India)   | Continuous generalized seizures lasting ≥10 min or two or more discrete seizures without complete recovery of consciousness in between | Reported           | PHT 50 VPA 50 LEV 50 | PHT 6.7 ± 6.53 h VPA 7.38 ± 8.39 h LEV 10.18 ± 9.33 h | PHT 20 mg/kg i.v. VPA 30 mg/kg i.v. LEV 25 mg/kg i.v. in hospital | Mortality | Seizure control | LZP (0.1 mg/kg; 4–6 mg i.v.) was given within 5 min of arrival |
| First author, year (country) | Definition of SE and inclusion criteria | Underlying etiology | No. of patients | Duration of SE | Interventions | Outcomes | Notes |
|-----------------------------|----------------------------------------|---------------------|----------------|---------------|---------------|----------|-------|
| Shaner, 1988 (USA)          | History of 30 min of continuous generalized convulsive seizures and witnessed generalized seizures | Reported            | PHT 18 PB 18   | NR            | PHT 18 mg/kg i.v. PB 10 mg/kg i.v. in hospital | Seizure control Adverse effects | DZP was infused at 2 mg/min i.v. only in the PHT group |
| Treiman, 1998 (USA)         | Two or more generalized convulsions without full recovery of consciousness between seizures or continuous convulsive activity for more than 10 min | Reported            | LZP 100 PB 92  PHT 203 | NR            | LZP 0.1 mg/kg i.v. PB 15 mg/kg i.v. DZP/PHT 0.15 and 18 mg/kg i.v. PHT 18 mg/kg i.v. | Seizure control Adverse effects | |

Abbreviations: DZP, diazepam; LEV, levetiracetam; LZP, lorazepam; NR, not reported; PB, phenobarbital; PHT, phenytoin; VPA, valproate.
Fig 2. Risk of bias summary of the included studies comparing phenytoin and other antiepileptic drugs as treatments for status epilepticus in adults. A, Seizure cessation. B, Mortality. C, Good neurological outcome.
However, a comparison of PHT and PB revealed significant heterogeneity ($I^2 = 76\%$, $\chi^2 = 4.08$, $p = 0.04$).

**Publication bias**

We assessed publication bias for each outcome by constructing a funnel plot. A visual inspection of the funnel plots suggested no publication bias was observed for mortality, a good neurological outcome, or the cessation of seizures (see Fig. S1).

**DISCUSSION**

**Summary of results**

This systematic review evaluated the evidence from RCTs comparing outcomes between i.v. PHT and other i.v. antiepileptic medications (VPA, LEV, and PB) given to adult patients receiving second-line treatment for benzodiazepine-refractory convulsive SE. The 10 RCTs retrieved in this study were published from 1988 to 2018 and carried out in hospital settings. Phenytoin was significantly inferior to other medications in terms of the cessation of seizures.
Therefore, we subsequently undertook subgroup analyses for seizure cessation using pairwise comparisons of PHT and VPA, LEV, or PB. No significant differences in the effects of PHT versus VPA, PHT versus LEV, or PHT versus PB were observed ($p = 0.07$, $p = 0.99$, and $p = 0.62$, respectively) (Fig. 4). No statistically significant difference was found regarding mortality or good neurological outcomes. However, significant heterogeneity was observed in the comparison between PHT and PB.

In our systematic review, the results of this meta-analysis of RCTs showed no significant difference between PHT and other drugs when pairwise comparisons were carried out between PHT and VPA, LEV, or PB. In other words, it can be inferred that there is no difference in efficacy between PHT and other antiepileptic medications in terms of seizure cessation. One possible reason why the difference in the pairwise comparisons was not significant was a low statistical power due to the large number of studies with small case numbers in this study. For example, when comparing VPA and PHT, VPA was not significantly superior in seizure cessation, but it did show a greater tendency than PHT. A recently published RCT on SE has reported novel results: LEV, fosphenytoin, and VPA each led to seizure cessation and improved alertness at 60 min in approximately half of patients with benzodiazepine-refractory convulsive SE.

Fig 4. Forest plots of the comparisons of studies comparing phenytoin and other antiepileptic drugs as treatments for status epilepticus in adults (subgroup analyses for seizure cessation). A, Phenytoin versus valproate for seizure cessation. B, Phenytoin versus levetiracetam for seizure cessation. C, Phenytoin versus phenobarbital for seizure cessation. CI, confidence interval; M-H, Mantel–Haenszel method.

© 2022 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine
Table 2. Evidence profile comparing phenytoin with other drugs for status epilepticus

| Certainty assessment | No of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | No of patients | Effect | Certainty | Importance |
|----------------------|---------------|--------------|--------------|---------------|--------------|-------------|---------------------|---------------|--------|-----------|------------|
| Seizure cessation    | 10 Randomized trials | Serious* | Not serious | Serious† | Not serious | None | 313/485 (64.5%) | 381/527 (72.3%) | RR 0.89 (0.82 to 0.97) | 80 fewer per 1,000 (from 130 fewer to 22 fewer) | ⨁◯◯◯ | Low       | Critical   |
| Mortality at discharge | 4 Randomized trials | Serious‡ | Not serious | Serious§ | Very serious§ | None | 16/149 (10.7%) | 15/149 (10.1%) | RR 1.07 (0.55 to 2.08) | 7 more per 1,000 (from 45 fewer to 109 more) | ⨁◯◯◯ | Very low  | Critical   |
| Good neurological outcome | 2 Randomized trials | Serious* | Not serious | Serious¶ | Serious** | None | 30/52 (57.7%) | 33/41 (80.5%) | RR 0.91 (0.72 to 1.19) | 72 fewer per 1,000 (from 225 fewer to 121 more) | ⨁◯◯◯ | Very low  | Critical   |

CI, confidence interval; RR, risk ratio.
*Allocation is not blinded in 2 cases, and concealment of allocation is not clear in 7 cases. The trial is being discontinued early in one case.
†The control antiepileptic drugs vary from study to study.
‡Allocation is not blinded in 1 case, and concealment of allocation is not clear in 3 cases.
§The outcome of one RCT was a 7-day mortality rate, with a large contribution rate of 47.5%.
¶Allocation is not blinded in one case, and concealment of allocation is not clear in one case.
**Different studies have different methods of assessing neurological outcomes.
††The sample size is smaller than OIS. Also, 95% CI contains considerable harm.
‡‡The sample size is smaller than OIS. Also, 95% CI includes both considerable benefits and harms.
and PB. Shaner et al. reported 36 consecutive patients with generalized convulsive SE who were treated with either a combination of diazepam (DZP) and PHT or PB.27 The total time spent in active convulsive movements was shorter for the PB group than for the DZP/PHT group (median, 5 versus 9 min, \( p < 0.06 \)). In all patients, however, convulsions were controlled within 7 h. Treiman et al. reported 570 patients with generalized convulsive SE who were randomly assigned to receive i.v. treatment with lorazepam, PB, PHT, or DZP followed by PHT. Among the 134 patients with a verified diagnosis of subtle generalized convulsive SE, no significant differences among the drugs were detected (range of success rates, 7.7–24.2%). In an intention-to-treat analysis, the differences among drugs were not significant, either among the patients with overt SE (\( p = 0.12 \)) or among those with subtle SE (\( p = 0.91 \)). Although the definition of seizures differed in these two RCTs, neither drug was significantly different in terms of its effects on seizure cessation. Therefore, the heterogeneity that existed between PHT and PB might have been due to the difference in the definition of seizures in these two reports.

**Comparison with previous study**

Two systematic reviews published in 201431 and 201932 compared the efficacy of five antiepileptic medications (VPA, lacosamide, LEV, PB, and PHT) as treatments for benzodiazepine-refractory convulsive SE. One study evaluated the efficacy and safety of i.v. VPA treatment for SE. Three randomized controlled trials compared i.v. VPA with i.v. PHT, two with i.v. diazepam, and one with i.v. PB. Valproate appeared to be an effective therapeutic option for patients with established benzodiazepine-refractory convulsive SE. However, no significant difference in seizure cessation was observed between PHT and VPA.31 Additionally, another study aimed to estimate the comparative efficacy and safety of AEDs in adults with benzodiazepine-resistant convulsive SE. Five comparative RCTs were included, as follows: i.v. VPA versus PHT, i.v. LEV versus PHT, i.v. LCM versus VPA, DZP versus VPA, and PB versus VPA. The study results were reported according to the recommendations of the PRISMA extension statement for network meta-analyses. This study suggested that high-dose PB was effective at controlling SE and preventing seizure recurrence.32 In that study, none of the included publications directly compared PB and PHT.

Our systematic review included more RCTs than either of the two prior reports. In addition, this study included a subgroup analysis of seizure cessation by pairwise comparison of PHT and VPA, LEV, or PB; no such analysis was reported in the previous studies.

**Clinical implications**

No significant difference was observed between PHT and VPA, LEV, or PB in terms of seizure cessation. Therefore, in clinical practice, clinicians may select the second-line treatment for adult SE from among these four drugs according to their customary practice and the insurance coverage available in the country.

**Strengths and limitations**

This study was the first systematic review to examine the effect of PHT on SE. Nonetheless, the present study has several limitations. First, all but one of the included studies had small sample sizes.28 Second, this study compares PHT to other AEDs but does not determine which AED is best. A network meta-analysis would be useful for addressing this question. Third, clinical rather than electroencephalographic criteria were used to determine the primary outcome of seizure cessation. Therefore, continuous electroencephalographic monitoring was not necessarily carried out. Finally, we were unable to assess the safety of the antiepileptic medications.

To date, no high-quality, evidence-based data are available to suggest the superiority of one AED over another in the treatment of benzodiazepine-refractory convulsive SE, and further head-to-head comparative studies are urgently needed.

**CONCLUSIONS**

The results of this meta-analysis of RCTs showed that i.v. PHT was significantly inferior to other medications in terms of the cessation of seizures. No significant differences were observed between PHT and other medications in terms of mortality or neurological outcomes in adult patients with SE.

**ACKNOWLEDGMENTS**

We would like to thank all members of the JRC Neuroresuscitation Task Force: Yasuhiko Ajimi, Masaaki Iwase, Kyoko Unemoto, Junji Kumawasa, Jun Goto, Hitoshi Kobata, Yutaka Kondo, Atsushi Sawamura, Toru Hifumi, Eisei Hoshiyama, Mitsuru Honda, Yasuhiro Norisue, Shoji Matsumoto, Yasufumi Miyake, Takashi Moriya, Hideto Yasuda, Tomoaki Yatabe, Kazuma Yamakawa, Sunghoon Yang,
Shoji Yokobori, Masahiro Wakasugi, and Masao Nagayama. We would like to thank the staff at the Japan Council for Quality Health Care (Minds Tokyo GRADE Center) for their assistance with the GRADE approach.

**DISCLOSURE**

Approval of the research protocol: N/A.
Informed consent: N/A.
Registry and registration no. of the study/trial: University Hospital Medical Information Network (UMIN-CTR) No. R000045525.
Animal studies: N/A.
Conflict of interest: None.

**REFERENCES**

1. Brophy GM, Bell R, Claassen J et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit. Care 2012; 17: 3–23.
2. Trinka E, Cock H, Hesdorffer D et al. A definition and classification of status epilepticus—report of the ILAE task force on classification of status Epilepticus. Epilepsia 2015; 56: 1515–23.
3. Claassen J, Goldstein JN. Emergency neurological life support: status epilepticus. Neurocrit. Care 2017; 27(Suppl 1): 152–8.
4. Silbergleit R, Durkalski V, Lowenstein D et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N. Engl. J. Med. 2012; 366: 591–600.
5. Allerdredge BK, Gelb AM, Isaacs SM et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N. Engl. J. Med. 2001; 345: 631–7.
6. Chamberlain JM, Okada P, Holsti M et al. Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. JAMA 2014; 311: 1652–60.
7. Glauser T, Shinnar S, Gloss D et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. Epilepsia Curr. 2016; 16: 48–61.
8. Claassen J, Hirsch LJ, Mayer SA. Treatment of status epilepticus: a survey of neurologists. J. Neurol. Sci. 2003; 211: 37–41.
9. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J. Clin. Epidemiol. 2009; 62: e1–34.
10. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6: e1000097.
11. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I² index? Psychol. Methods 2006; 11: 193–206.
12. Cochrane handbook for systematic reviews of interventions. Available from: https://training.cochrane.org/handbook/current/chapter-10#section-10-10.
13. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–60.
14. Higgins JPT, Altman DG, Sterne JAC, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions. Hoboken: Wiley-Blackwell, 2011 [cited 1 Apr 2021] [version 5.1.0. Available from: http://www.cochrane-handbook.org. Chapter 8.
15. Duan EH, Oczkowski SJ, Belley-Cote E et al. Beta-blockers in sepsis: protocol for a systematic review and meta-analysis of randomised control trials. BMJ Open 2016; 6: e012466.
16. Atkins D, Eccles M, Flottorp S et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches the GRADE Working Group. BMC Health Serv. Res. 2004; 4: 38.
17. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
18. Mustafa RA, Santesso N, Brozek J et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. J. Clin. Epidemiol. 2013; 66: 736–42; quiz 42.e1-42.e5.
19. Guyatt GH, Oxman AD, Schunemann HJJ, Tugwell P, Kno- terness A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J. Clin. Epidemiol. 2011; 64: 380–2.
20. Agarwal P, Kumar N, Chandra R et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 2007; 16: 527–32.
21. Amiri-Nikpour MR, Nazarbaghi S, Eftekhar P et al. Sodium valproate compared to phenytoin in treatment of status epilepticus. Brain Behav. 2018; 8: e00951.
22. Gilad R, Izkovitz N, Dabby R et al. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol. Scand. 2008; 118: 296–300.
23. Gujjar AR, Nandhagopal R, Jacob PC et al. Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study. Seizure 2017; 49: 8–12.
24. Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 2006; 67: 340–2.
25. Chakravarthi S, Goyal MK, Modi M et al. Levetiracetam versus phenytoin in management of status epilepticus. J. Clin. Neurosci. 2015; 22: 959–63.
26. Mundlamuri RC, Shinha S, Subbakrishna DK et al. Management of generalised convulsive status epilepticus (SE): a
prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam – Pilot study. Epilepsy Res. 2015; 114: 52–8.

27 Shaner DM, SA MC, Herring MO et al. Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neurology 1988; 38: 202–7.

28 Treiman DM, Meyers PD, Walton NY et al. A comparison of four treatments for generalized convulsive status epilepticus. N. Engl. J. Med. 1998; 339: 792–298.

29 Chitsaz A, Mehvari J, Salari M, Gholami F, Najafi MR. A comparative assessment the efficacy of intravenous infusion of sodium valproate and phenytoin in the treatment of status epilepticus. Int. J. Prev. Med. 2013; 4(Suppl 2): S216–21.

30 Kapur J, Elm J, Chamberlain JM et al. Randomized trial of three anticonvulsant medications for status epilepticus. N. Engl. J. Med. 2019; 381: 2103–13.

31 Trinka E, Hößler J, Zerbs A, Brigo F. Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS Drugs 2014; 28: 623–39.

32 Brigo F, Giovane CD, Nardone R et al. Intravenous antiepileptic drugs in adults with benzodiazepine-resistant convulsive status epilepticus: a systematic review and network metaanalysis. Epilepsy Behav. 2019; 101: 106466.

SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site:

Fig. S1. (A) Funnel plot of seizure cessation. (B) Funnel plot of mortality. (C) Funnel plot of a good neurological outcome.

File S1. Search strategies.